Search

Displaying results 271 - 280 of 331 in total
  1. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn.

  2. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  3. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.

  4. Drug

    Masitinib

    go.drugbank.com/drugs/DB11526
    InvestigationalVet approved

    It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

  5. Drug

    Aceclofenac

    go.drugbank.com/drugs/DB06736
    Approved

    It is a more commonly prescribed drug in Europe.

  6. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118] … [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries

  7. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.

  8. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    [A225953,A225958] On December 11, 2020, the European Commission (EC) granted authorization for marketing inclisiran as the first and only approved siRNA for the treatment of adults with primary hypercholesterolemia

  9. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    Azetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da.

  10. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.